RPL31 Antibody

What is RPL31 and why is it significant in research?

RPL31 (Ribosomal Protein L31) is a component of the 60S large ribosomal subunit, belonging to the L31E family of ribosomal proteins. Located in the cytoplasm, it plays a crucial role in ribosome self-assembly, protein synthesis, and cellular proliferation .

Beyond its fundamental role in protein translation, RPL31 has gained research significance because:

• It is an important constituent of the peptidyltransferase center

• It has been implicated in DNA repair and tumorigenesis mechanisms

• Altered expression has been observed in several cancer types, including prostate and gastric cancers

The protein has a molecular weight of approximately 14 kDa, with the human gene located on chromosome 2 (2q11.2) .

What applications are RPL31 antibodies validated for?

RPL31 antibodies have been validated for multiple research applications:

Importantly, optimal dilutions should be determined by individual researchers for their specific experimental systems .

What species reactivity can be expected from RPL31 antibodies?

Most commercially available RPL31 antibodies have been tested for reactivity with:

• Human (confirmed)

• Mouse (confirmed)

• Rat (confirmed)

Some antibodies are predicted to react with additional species due to high sequence homology:

• Cow, Pig, and Xenopus (predicted but may require validation)

When selecting an antibody for cross-species applications, check the immunogen sequence identity with the target species .

How should I optimize Western blot protocols for RPL31 detection?

For optimal Western blot detection of RPL31:

• Sample preparation:

  • Use appropriate lysis buffers for cytoplasmic protein extraction

  • Load 30 μg of whole cell extract as demonstrated in validated protocols

• Gel selection:

  • Use 15% SDS-PAGE gels for optimal resolution of the 14 kDa RPL31 protein

• Antibody dilution:

  • Primary antibody: Start with 1:500-1:1000 dilution

  • Secondary antibody: Use species-appropriate HRP-conjugated secondary antibody

• Expected results:

  • Target band should appear at approximately 14 kDa

  • Validate specificity using RPL31 knockdown controls

• Positive controls:

  • HepG2, HeLa, or HEK-293T cell lysates have been validated for detecting RPL31

What are the recommended approaches for using RPL31 antibodies in cancer research?

Based on recent studies, the following approaches are recommended for cancer-related RPL31 research:

• Expression analysis:

  • Compare RPL31 levels between tumor and adjacent normal tissues using IHC

  • Quantify with appropriate scoring systems (>3 considered high expression in gastric cancer studies)

• Functional studies:

  • RNA interference: Use validated siRNA or shRNA sequences for knockdown studies

    • Validated target sequence examples: 5'-TGGGCCAAAGGAATAAGGAAT-3', 5'-GCACTCAAAGAGATTCGGAAA-3', 5'-CCGAGAATACACCATCAACAT-3'

  • Assess effects on:

    • Cell proliferation and viability

    • Migration and invasion capabilities

    • Apoptosis markers

    • Cell cycle distribution

• Mechanistic investigations:

  • Examine relationship between RPL31 and p53 pathway components (p21, MDM2)

  • Assess impacts on protein synthesis and ribosome biogenesis

How can I design experiments to study RPL31 interaction with other ribosomal proteins?

To study RPL31 interactions with other ribosomal components:

• Cross-linking approaches:

  • Zero-length cross-linker EDC (1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride) at 20 mM concentration for direct interaction detection

  • BS3 cross-linking at 0.8 mM final concentration (21°C for 20 min) for detecting proximity-based interactions

  • Stop reactions with appropriate quenchers (glycyl-glycine at 30 mM for BS3)

• Co-immunoprecipitation:

  • Use purified ribosomes (56 nM concentration) or cell lysates

  • Analyze by SDS-PAGE followed by immunoblotting

  • Probe for suspected interaction partners (e.g., ribosome-associated complex components)

• Genetic approaches:

  • Study epistatic relationships through double/triple deletion analyses as demonstrated with RPL31a/b and RPL39

  • Test for genetic suppression (e.g., multicopy suppressor screening)

How can I investigate the role of RPL31 in cancer cell resistance mechanisms?

To study RPL31's role in cancer therapy resistance:

• Resistance model development:

  • Establish resistant cell lines through long-term exposure to therapeutic agents (e.g., bicalutamide-resistant prostate cancer model)

  • Compare RPL31 expression between parental and resistant cells

• Functional validation:

  • Perform shRNA/siRNA-mediated functional screening to identify RPL31 as a candidate gene modulating response to therapeutics

  • Use volcano plot analysis to screen genes involved in drug response

• Molecular mechanism exploration:

  • Examine how RPL31 knockdown affects:

    • p53 protein stability and degradation rates

    • Expression of p53 targets (p21, MDM2)

    • Cell cycle progression

  • Conduct rescue experiments with p53 siRNA to confirm pathway involvement

• Clinical correlation:

  • Analyze public datasets (ONCOMINE, TCGA) to correlate RPL31 expression with treatment outcomes

What methodologies can be used to study RPL31's role in ribosome biogenesis and protein synthesis?

To investigate RPL31's function in ribosome biogenesis:

• Ribosome profiling:

  • Compare ribosome assembly and polysome profiles between wild-type and RPL31-depleted cells

  • Analyze changes in translation efficiency and ribosome occupancy

• Translational fidelity assays:

  • Assess translational fidelity using reporter systems in RPL31-deficient models

  • Examine sensitivity to aminoglycoside antibiotics, which indicates altered translational fidelity

• Growth condition sensitivities:

  • Test growth at varying temperatures (low and high) as RPL31-deficient yeast shows temperature sensitivity

  • Evaluate growth under nutrient limitation or stress conditions

• Structural studies:

  • Examine RPL31's position near the ribosomal tunnel exit

  • Investigate interactions with ribosome-associated complexes that facilitate nascent chain folding

How can I determine if RPL31 has extraribosomal functions in my experimental system?

To explore potential extraribosomal functions of RPL31:

• Subcellular localization:

  • Use fractionation techniques to separate cytoplasmic, nuclear, and ribosomal fractions

  • Confirm RPL31 distribution using immunofluorescence with appropriate controls

• Protein-protein interaction screening:

  • Perform immunoprecipitation coupled with mass spectrometry to identify non-ribosomal interaction partners

  • Validate key interactions with co-IP and reciprocal pull-downs

• Conditional depletion strategies:

  • Use inducible knockdown systems to distinguish acute vs. chronic effects

  • Compare phenotypes with knockdown of other ribosomal proteins to identify RPL31-specific effects

• Transcriptomic and proteomic analyses:

  • Conduct RNA-seq and proteomics on RPL31-depleted cells

  • Look for signature patterns distinct from general translation inhibition

How should I interpret conflicting results regarding RPL31's role in cancer progression?

When addressing conflicting data about RPL31 in cancer:

• Consider cancer type specificity:

  • RPL31 shows oncogenic properties in prostate and gastric cancers

  • Some studies suggest inhibitory functions in other contexts (e.g., recombinant RPL31 from giant panda)

• Evaluate experimental approaches:

  • Cell line vs. primary tissue differences

  • Knockdown vs. overexpression methodologies

  • Timing of observations (acute vs. chronic effects)

• Examine p53 status in your model:

  • RPL31's effects may depend on p53 functionality (knockdown increases p53 levels)

  • Test in both p53 wild-type and p53-deficient backgrounds

• Analyze context-dependent signaling:

  • Relationship with PI3K pathway, which targets ribosomal proteins in growth regulation

  • Potential interaction with other oncogenic or tumor suppressor pathways

What controls are essential when using RPL31 antibodies to study ribosome function?

Essential controls for ribosome function studies:

• Antibody validation controls:

  • Positive controls: Lysates from cells known to express RPL31 (HepG2, HeLa)

  • Negative controls: RPL31 knockdown cells or tissues

• Specificity controls:

  • Pre-absorption with immunizing peptide when available

  • Detection of expected molecular weight (14 kDa)

• Loading controls:

  • Use established ribosomal proteins (e.g., Rpl17, Rps9) for normalization between samples

  • Non-ribosomal proteins (e.g., Sse1) as general loading controls

• Experimental controls:

  • Compare with other 60S ribosomal proteins to distinguish specific vs. general effects

  • Include translation inhibitors (cycloheximide, puromycin) as reference points

How can I address non-specific binding issues when using RPL31 antibodies in complex samples?

To minimize non-specific binding:

• Optimization strategies:

  • Titrate antibody concentrations (start with manufacturer's recommendations, then optimize)

  • Adjust blocking conditions (concentration, time, blocking agent)

  • Optimize incubation times and temperatures

• Sample preparation considerations:

  • Ensure complete lysis and denaturation for Western blot applications

  • For IHC/IF, test different fixation protocols and antigen retrieval methods

• Cross-reactivity minimization:

  • Pre-clear lysates with protein A/G beads before immunoprecipitation

  • Increase wash stringency (salt concentration, detergent type/amount)

  • Use monoclonal antibodies when high specificity is required

• Validation approaches:

  • Confirm results with multiple antibodies targeting different epitopes of RPL31

  • Include peptide competition assays to confirm specificity

  • Validate key findings with orthogonal techniques (e.g., mass spectrometry)